CN118497276A - 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 - Google Patents
腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 Download PDFInfo
- Publication number
- CN118497276A CN118497276A CN202410531995.8A CN202410531995A CN118497276A CN 118497276 A CN118497276 A CN 118497276A CN 202410531995 A CN202410531995 A CN 202410531995A CN 118497276 A CN118497276 A CN 118497276A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid substitutions
- amino acids
- amino
- cell target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 295
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 223
- 210000004027 cell Anatomy 0.000 title abstract description 156
- 210000002768 hair cell Anatomy 0.000 title abstract description 126
- 210000003027 ear inner Anatomy 0.000 title description 24
- 230000014509 gene expression Effects 0.000 title description 18
- 230000007547 defect Effects 0.000 title description 6
- 239000013603 viral vector Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 141
- 239000013598 vector Substances 0.000 claims abstract description 139
- 241000288906 Primates Species 0.000 claims abstract description 96
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 78
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 73
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 73
- 238000002744 homologous recombination Methods 0.000 claims abstract description 8
- 230000006801 homologous recombination Effects 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1259
- 108091026890 Coding region Proteins 0.000 claims description 71
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 239000002773 nucleotide Substances 0.000 claims description 63
- 125000000539 amino acid group Chemical group 0.000 claims description 36
- 108700024394 Exon Proteins 0.000 claims description 34
- 108020004414 DNA Proteins 0.000 claims description 26
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 239000013607 AAV vector Substances 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 2386
- 238000006467 substitution reaction Methods 0.000 description 1260
- 229940024606 amino acid Drugs 0.000 description 1135
- 150000001413 amino acids Chemical class 0.000 description 1135
- 230000008093 supporting effect Effects 0.000 description 96
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 92
- 108010076504 Protein Sorting Signals Proteins 0.000 description 54
- 238000000034 method Methods 0.000 description 40
- 230000035772 mutation Effects 0.000 description 32
- 102000053602 DNA Human genes 0.000 description 25
- 229920002477 rna polymer Polymers 0.000 description 23
- 210000004899 c-terminal region Anatomy 0.000 description 22
- 239000003550 marker Substances 0.000 description 22
- 210000000717 sertoli cell Anatomy 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 20
- 206010011878 Deafness Diseases 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 231100000888 hearing loss Toxicity 0.000 description 12
- 230000010370 hearing loss Effects 0.000 description 12
- 208000016354 hearing loss disease Diseases 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 230000008488 polyadenylation Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 206010011891 Deafness neurosensory Diseases 0.000 description 8
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 8
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108700026220 vif Genes Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 5
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 description 5
- 102100035278 Pendrin Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 101710093463 Clarin-1 Proteins 0.000 description 4
- 108050001616 Pendrin Proteins 0.000 description 4
- 101150030803 SLC26A4 gene Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102100031060 Clarin-1 Human genes 0.000 description 3
- 101150034593 Gjb2 gene Proteins 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102100040191 Alpha-tectorin Human genes 0.000 description 2
- 102100022509 Cadherin-23 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101150105682 HSPA1A gene Proteins 0.000 description 2
- 101000889766 Homo sapiens Alpha-tectorin Proteins 0.000 description 2
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 description 2
- 101000635935 Homo sapiens Myosin-IIIa Proteins 0.000 description 2
- 101100297724 Homo sapiens PJVK gene Proteins 0.000 description 2
- 101001072259 Homo sapiens Protocadherin-15 Proteins 0.000 description 2
- 101000801040 Homo sapiens Transmembrane channel-like protein 1 Proteins 0.000 description 2
- 101000649014 Homo sapiens Triple functional domain protein Proteins 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100030743 Myosin-IIIa Human genes 0.000 description 2
- 101150025720 NDP gene Proteins 0.000 description 2
- 101150006256 Otof gene Proteins 0.000 description 2
- 102100034198 Otoferlin Human genes 0.000 description 2
- 108050006335 Otoferlin Proteins 0.000 description 2
- 101710135791 Pejvakin Proteins 0.000 description 2
- 102100036328 Pejvakin Human genes 0.000 description 2
- 102100036382 Protocadherin-15 Human genes 0.000 description 2
- 108050006373 Stereocilin Proteins 0.000 description 2
- 102000016796 Stereocilin Human genes 0.000 description 2
- 101150044746 Strc gene Proteins 0.000 description 2
- 101150049497 TRIOBP gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101150072076 Tmc1 gene Proteins 0.000 description 2
- 102100033690 Transmembrane channel-like protein 1 Human genes 0.000 description 2
- 102100028101 Triple functional domain protein Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100031834 Unconventional myosin-VI Human genes 0.000 description 2
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 description 2
- 102100029836 Unconventional myosin-XV Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 102100038102 Whirlin Human genes 0.000 description 2
- 101710155241 Whirlin Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010049787 myosin VI Proteins 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001323 spiral ganglion Anatomy 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
- 206010010280 Conductive deafness Diseases 0.000 description 1
- 108010077781 F-actin-binding proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 description 1
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 description 1
- 101001094048 Homo sapiens Pendrin Proteins 0.000 description 1
- 101000713234 Homo sapiens TRIO and F-actin-binding protein Proteins 0.000 description 1
- 101000585635 Homo sapiens Unconventional myosin-XV Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100031801 Nexilin Human genes 0.000 description 1
- 101710085992 Norrin Proteins 0.000 description 1
- 102100025036 Norrin Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100036855 TRIO and F-actin-binding protein Human genes 0.000 description 1
- 101710135185 Unconventional myosin-XV Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000023563 conductive hearing loss disease Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 101150101299 gene 4 gene Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000006790 nonsyndromic deafness Diseases 0.000 description 1
- 210000002985 organ of corti Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756953P | 2018-11-07 | 2018-11-07 | |
| US62/756,953 | 2018-11-07 | ||
| US201962888093P | 2019-08-16 | 2019-08-16 | |
| US62/888,093 | 2019-08-16 | ||
| PCT/US2019/060328 WO2020097372A1 (en) | 2018-11-07 | 2019-11-07 | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| CN201980082439.4A CN113853437A (zh) | 2018-11-07 | 2019-11-07 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980082439.4A Division CN113853437A (zh) | 2018-11-07 | 2019-11-07 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118497276A true CN118497276A (zh) | 2024-08-16 |
Family
ID=70611216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410531995.8A Pending CN118497276A (zh) | 2018-11-07 | 2019-11-07 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| CN201980082439.4A Pending CN113853437A (zh) | 2018-11-07 | 2019-11-07 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980082439.4A Pending CN113853437A (zh) | 2018-11-07 | 2019-11-07 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230056182A1 (https=) |
| EP (2) | EP4063510A1 (https=) |
| JP (2) | JP2022506613A (https=) |
| CN (2) | CN118497276A (https=) |
| AU (1) | AU2019377115A1 (https=) |
| CA (1) | CA3119065A1 (https=) |
| WO (1) | WO2020097372A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CN119410636A (zh) | 2018-04-27 | 2025-02-11 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| AU2020218547A1 (en) | 2019-02-08 | 2021-08-26 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| CA3159549A1 (en) | 2019-10-30 | 2021-05-06 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| JP7807380B2 (ja) | 2020-02-21 | 2026-01-27 | アコーオス インコーポレイテッド | ヒト対象において非加齢関連聴力障害を処置するための組成物および方法 |
| EP4164695A4 (en) * | 2020-05-13 | 2024-06-05 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS |
| US20240016955A1 (en) * | 2020-09-14 | 2024-01-18 | President And Fellows Of Harvard College | Dual-aav vector delivery of pcdh15 and uses thereof |
| JP2023541443A (ja) * | 2020-09-14 | 2023-10-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。 |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| AU2021376225A1 (en) * | 2020-11-06 | 2023-06-22 | Eli Lilly And Company | Variant adeno-associated virus (aav)capsid polypeptides and gene therapeutics thereof for treatment of hearing loss |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023007800A (es) | 2020-12-29 | 2023-07-11 | Akouos Inc | Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1. |
| US20220267795A1 (en) * | 2021-02-24 | 2022-08-25 | Kinase Pharma Inc. | Compositions and methods for regulating production of an angiogensis inhibitor |
| EP4473011A1 (en) * | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| KR20250080886A (ko) * | 2022-09-30 | 2025-06-05 | 데시벨 테라퓨틱스, 인크. | Slc26a4 조절 요소 및 이의 용도 |
| WO2025179016A1 (en) * | 2024-02-20 | 2025-08-28 | Skylark Bio, Inc. | Recombinant adeno associated virus and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0928202A4 (en) * | 1996-09-25 | 2001-09-05 | Cell Genesys Inc | NON-INVASIVE ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS |
| EP1082445A2 (en) * | 1998-05-27 | 2001-03-14 | Cell Genesys, Inc. | Adeno-associated viral vector-mediated expression of factor viii activity |
| WO2011075838A1 (en) * | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| CA2890061A1 (en) * | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
| CA2909733C (en) * | 2013-04-18 | 2023-10-17 | Fondazione Telethon | Effective delivery of large genes by dual aav vectors |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| TWI813532B (zh) * | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的ｃｒｉｓｐｒ酶突變 |
| SG11201804814YA (en) * | 2015-12-11 | 2018-07-30 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| WO2017136764A1 (en) * | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
| WO2017181021A1 (en) * | 2016-04-15 | 2017-10-19 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| JP2019530737A (ja) * | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
| KR102746901B1 (ko) * | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
-
2019
- 2019-11-07 CN CN202410531995.8A patent/CN118497276A/zh active Pending
- 2019-11-07 CN CN201980082439.4A patent/CN113853437A/zh active Pending
- 2019-11-07 JP JP2021524060A patent/JP2022506613A/ja active Pending
- 2019-11-07 WO PCT/US2019/060328 patent/WO2020097372A1/en not_active Ceased
- 2019-11-07 EP EP22155160.9A patent/EP4063510A1/en not_active Withdrawn
- 2019-11-07 EP EP19881503.7A patent/EP3880826A4/en not_active Withdrawn
- 2019-11-07 US US17/291,931 patent/US20230056182A1/en not_active Abandoned
- 2019-11-07 CA CA3119065A patent/CA3119065A1/en active Pending
- 2019-11-07 AU AU2019377115A patent/AU2019377115A1/en active Pending
-
2024
- 2024-03-25 JP JP2024048210A patent/JP2024086735A/ja active Pending
- 2024-08-15 US US18/806,641 patent/US20250041457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020097372A8 (en) | 2021-04-29 |
| US20230056182A1 (en) | 2023-02-23 |
| US20250041457A1 (en) | 2025-02-06 |
| EP4063510A1 (en) | 2022-09-28 |
| JP2024086735A (ja) | 2024-06-28 |
| CN113853437A (zh) | 2021-12-28 |
| JP2022506613A (ja) | 2022-01-17 |
| EP3880826A1 (en) | 2021-09-22 |
| AU2019377115A1 (en) | 2021-05-20 |
| EP3880826A4 (en) | 2022-08-24 |
| CA3119065A1 (en) | 2020-05-14 |
| WO2020097372A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118497276A (zh) | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 | |
| US12264317B2 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| US20220040327A1 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| JP7807380B2 (ja) | ヒト対象において非加齢関連聴力障害を処置するための組成物および方法 | |
| US12275960B2 (en) | AAV-mediated delivery of therapeutic antibodies to the inner ear | |
| JP2023153320A (ja) | Ｃｌｒｎ１に関連する聴力喪失及び／または視力喪失を治療する方法 | |
| CN118679182A (zh) | 用于治疗前庭神经鞘瘤相关症状的抗vegf抗体构建体和相关方法 | |
| KR20230117179A (ko) | 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법 | |
| HK40115203A (zh) | 腺相关病毒载体用於在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 | |
| JP2024500786A (ja) | Ｃｌｒｎ１関連難聴及び／または視力低下を治療するための組成物及び方法 | |
| EA051334B1 (ru) | Композиции и способы лечения невозрастных нарушений слуха у человека | |
| EA052823B1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40115203 Country of ref document: HK |